1,680 reports of this reaction
1.7% of all CONJUGATED ESTROGENS reports
#9 most reported adverse reaction
BREAST CANCER METASTATIC is the #9 most commonly reported adverse reaction for CONJUGATED ESTROGENS, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. There are 1,680 FDA adverse event reports linking CONJUGATED ESTROGENS to BREAST CANCER METASTATIC. This represents approximately 1.7% of all 100,524 adverse event reports for this drug.
Patients taking CONJUGATED ESTROGENS who experience breast cancer metastatic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER METASTATIC is a less commonly reported adverse event for CONJUGATED ESTROGENS, but still significant enough to appear in the safety profile.
In addition to breast cancer metastatic, the following adverse reactions have been reported for CONJUGATED ESTROGENS:
The following drugs have also been linked to breast cancer metastatic in FDA adverse event reports:
BREAST CANCER METASTATIC has been reported as an adverse event in 1,680 FDA reports for CONJUGATED ESTROGENS. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER METASTATIC accounts for approximately 1.7% of all adverse event reports for CONJUGATED ESTROGENS, making it a notable side effect.
If you experience breast cancer metastatic while taking CONJUGATED ESTROGENS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.